The beta-adrenergic blocking drug, propranolol, was introduced by Black and associates in 1964. Since the sympathetic receptors in bronchial smooth muscle are beta in type, there was the possibility that the administration of propranolol would give rise to bronchoconstriction. This was confirmed by McNeill (1964) who showed that propranolol could cause a marked reduction in the forced expiratory volume (FEVj) of some asthmatic subjects and supporting evidence has come from Meier, Lydtin and Zollner (1966) and Zaid and Beall (1966) . Using the more sensitive method of measuring airway resistance (AWR) by whole-body plemysmography, McNeill and Ingram (1966) and Macdonald, Ingram and McNeill (1967) have shown that propranolol also affects the airways of normal subjects although in them it very rarely gives rise to dyspnoea and wheezing. Investigations into the mechanism of the effect of propranolol on the airways by the latter group indicate that when the beta receptors are blocked, bronchoconstriction occurs as a result of unopposed vagal activity. Atropine mitigates the effect of propranolol but cannot be relied upon to protect the sensitive asthmatic subject completely and therefore the introduction of the new cardioselective beta-adrenergic blocking agent ICI.50,172 (Barrett et al., 1967) is potentially an important advance. This trial has been undertaken to assess its effect on airway resistance of asthmatic subjects and to compare its activity with that of propranolol.
SUBJECTS AND METHODS
Five male and five female asthmatic subjects, with ages varying* from 16 to 58 years, were studied. Two were mild asthmatics and eight were moderately severe, two requiring maintenance steroid therapy. The nature of the investigation and the possibility of causing temporary aggravation of their condition was explained to the subjects who readily agreed to take part.
Airway resistance was measured by the whole body plethysmograph method of Dubois, Botelho and Comroe (1956) , and the FEV 1 on a Vitalograph. Pulse rate was counted and measurements of AWR and FEVi were made alternately at 3 to 5-minute intervals both before and after drug administration. For technical reasons only FEV, measurements were obtained on subject No. 8, and no FEV! measurements after propranolol were made on subject No. 1. The drugs were given intravenously over 30 seconds on different days and all subjects received ICI.50,172 15 mg and propranolol 5 mg, with the exception of No. 7 who received only 1 mg of propranolol, and subjects No. 9 and 10 who each received only 2 mg of propranolol, because of moderate disability on the day of study. Measurements were continued up to 1 hour after drug administration or until it was obvious that the peak effects of the drug had passed. The survey began as a double-blind trial, but subject No. 2 developed severe bronchospasm 10 minutes after receiving the unknown drug, and it was considered unjustified to continue without knowing whether it was propranolol which had produced this marked response, or ICI.50,172 which had produced an unexpected response which might have been less easily treated. In this case, the seal was broken and the drug given was revealed as propranolol, but it was not felt justified in continuing the trial on a double-blind basis.
RESULTS
The effects of propranolol and ICI.50,172 on AWR are shown in table I. All the peak values stated occurred within 20 minutes and usually between 2 and 10 minutes of drug administration. After propranolol all subjects except No. 5 became breathless and more wheezy and there was a marked rise in AWR (mean % rise 175.7; SD ±136.5; SE ±45.5). In five the wheeze subsided after about 30 minutes but in the four subjects most severely affected it persisted and required treatment with intravenous aminophylline. Subject No. 7 who, as already stated, was wheezy before receiving propranolol and was therefore given only 1 mg, deteriorated after 2 minutes and was given aminophylline and atropine which relieved her condition. After 11 ICI.50,172 none of the subjects became breathless or more wheezy, although in most subjects there was a slight increase in AWR (mean % rise 22.6; SD ±31.2; SE ±10.4). There is a significant difference between the effects of these drugs on AWR (P<0.01).
The effects of both drugs on FEV\ are shown in table II and the results in each subject correlate well with the changes in AWR. All subjects except No. 5 had a marked fall in FEVj after propranolol but only a slight fall after ICI.50,172. The effects of the two drugs on pulse rate are shown in table HI. Although the mean values before and after ICI.50,172 are higher than the corresponding ones for propranolol the percentage fall in pulse rate is comparable. 
